Clinical trial with innovative therapy begins treating children with cancer
In May 2025, the first children with medulloblastoma received the experimental treatment in the MATCHPOINT study, representing an unprecedented breakthrough funded by MBI. While these initial patients begin therapy, new pediatric and young adult participants with recurrent or refractory medulloblastoma continue to be recruited for the clinical trial in the U.S. FDA-approved in 2024, the […]
MBI in the spotlight: a feature by MIT News
“The MBI blueprint for funding cures for rare diseases is replicable and likely to disrupt the standard way health care research is funded and carried out by radically shortening the timeline.” MBI has been highlighted by one of the most prestigious institutions in the world, MIT – Massachusetts Institute of Technology. An article showcasing our […]
MBI takes medulloblastoma fight to national spotlight on Fox 5
During Brain Cancer Awareness Month, Fernando Goldsztein, MBI’s founder, and Dr. Roger J. Packer, scientific leader, appeared live on FOX 5 DC to share details about our groundbreaking work. FOX 5, a regional affiliate of Fox Broadcasting Company, reaches over 200 million viewers daily across the U.S. Watch the full segment here. While awareness opens […]
